

Proxy Decision-making in a Deprescribing Trial in Nursing Home Residents with Dementia: a Qualitative Analysis

RATIONALE

- Due the need for proxy-consent, older adults with dementia are frequently excluded from experimental studies, leading to a questioned net benefit of many medical interventions in this population.
- With a greater risk of severe side-effects, a promising potential clinical target is the reduction of polypharmacy. Hence, older adults with dementia, and especially those living in a nursing home, form a preferable target for a randomized controlled trial (RCT) on deprescribing.

Question is: how do the informed consent procedure and the process of proxy decision-making on the participation in such an experimental trial take place?

CONCLUSION

The process of proxy decision-making on trial participation of older adults with dementia might be considered as a benefit-risk evaluation, guided by study and patient related factors that are weighted on level of the deciding proxy. Other involved proxies or treating healthcare professionals can modulate the final evaluation of these factors.











